Multi-target ABC transporter modulators: what next and where to go?

[...]generation small-molecule ABC transporter inhibitors were used at much lower dose, as they were significantly more potent than first-generation drugs such as verapamil. [...]it must be pondered: the potential risk of a new therapy against the death in the immediate future of relapsed/refractory cancer patients. [...]considering the characteristics of cancer-related MDR in general, such as the different modes. of resistance, drug penetration into the tumors., ABC transporter polymorphism or expression of multiple ABC transporters (3-6), the development of a targeted therapy in ABC transporter-driven cancer-related MDR is feasible. [...]data deviation has a certain impact on such novel methods, but this impact has limits and does not necessarily compromise the experimental outcome.